BR0009823A - Variant of the merozoite plasmodium (msp-1) surface protein and vaccine comprising the variant - Google Patents
Variant of the merozoite plasmodium (msp-1) surface protein and vaccine comprising the variantInfo
- Publication number
- BR0009823A BR0009823A BR0009823-0A BR0009823A BR0009823A BR 0009823 A BR0009823 A BR 0009823A BR 0009823 A BR0009823 A BR 0009823A BR 0009823 A BR0009823 A BR 0009823A
- Authority
- BR
- Brazil
- Prior art keywords
- variant
- msp
- plasmodium
- antibody
- vaccine
- Prior art date
Links
- 241000224016 Plasmodium Species 0.000 title abstract 7
- 102000018697 Membrane Proteins Human genes 0.000 title abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 210000003936 merozoite Anatomy 0.000 title 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000006337 proteolytic cleavage Effects 0.000 abstract 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 210000004900 c-terminal fragment Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"VARIANTE DA PROTEìNA DE SUPERFìCIE DE PLASMODIUM MEROZOITO (MSP-1) E VACINA COMPREENDENDO A VARIANTE". Variante que não ocorre naturalmente de um fragmento de terminal-C de uma proteína-1 (MSP-1) de superfície de Plasmodium merozoito, onde a variante possui (i) uma afinidade reduzida, em comparação ao Plasmodium MSP-1~ 19~ que ocorre naturalmente, para pelo menos um primeiro anticorpo capaz de bloquear a ligação de um segundo anticorpo, o segundo anticorpo inibindo a clivagem proteolítica de Plasmodium MSP-1~ 42~ e (ii) substancialmente a mesma afinidade para pelo menos um terceiro anticorpo em comparação ao Plasmodium MSP-19 que ocorre naturalmente, o terceiro anticorpo inibindo a clivagem proteolítica do Plasmodium MSP~1~ 42~."VARIANT TO THE SURFACE PROTEIN OF PLASMODIUM MEROZOITO (MSP-1) AND VACCINE UNDERSTANDING THE VARIANT". Non-naturally occurring variant of a C-terminal fragment of a protein-1 (MSP-1) on the surface of Plasmodium merozoito, where the variant has (i) a reduced affinity, compared to Plasmodium MSP-1 ~ 19 ~ which occurs naturally, for at least one first antibody capable of blocking the binding of a second antibody, the second antibody inhibiting the proteolytic cleavage of Plasmodium MSP-1 ~ 42 ~ and (ii) substantially the same affinity for at least one third antibody in comparison to the naturally occurring Plasmodium MSP-19, the third antibody inhibiting Plasmodium MSP ~ 1 ~ 42 ~ proteolytic cleavage.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9909072.2A GB9909072D0 (en) | 1999-04-20 | 1999-04-20 | Vaccine |
| US31181799A | 1999-05-13 | 1999-05-13 | |
| CA002271451A CA2271451A1 (en) | 1999-04-20 | 1999-05-25 | Variant c-terminal fragment of plasmodium falciparum msp-1 |
| PCT/GB2000/001558 WO2000063245A2 (en) | 1999-04-20 | 2000-04-20 | Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0009823A true BR0009823A (en) | 2002-04-09 |
Family
ID=27170966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0009823-0A BR0009823A (en) | 1999-04-20 | 2000-04-20 | Variant of the merozoite plasmodium (msp-1) surface protein and vaccine comprising the variant |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1180120A2 (en) |
| JP (1) | JP2002543774A (en) |
| CN (1) | CN1372568A (en) |
| AU (1) | AU779662B2 (en) |
| BR (1) | BR0009823A (en) |
| MX (1) | MXPA01010701A (en) |
| WO (1) | WO2000063245A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595191B2 (en) | 2001-01-26 | 2009-09-29 | The United States Of America As Represented By The Secretary Of The Army | Isolation and purification of P. falciparum merozoite protein-142 vaccine |
| EP1423421A2 (en) | 2001-01-26 | 2004-06-02 | Walter Reed Army Institute of Research | Isolation and purification of p. falciparum merozoite protein-1 42 vaccine |
| CN1176945C (en) * | 2001-02-01 | 2004-11-24 | 中国人民解放军第二军医大学 | Plasmodium fused antigen and its preparing process and usage |
| AU2003228441A1 (en) | 2002-04-01 | 2003-10-20 | The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research (Wrair) | Recombinant p. falciparum merozoite protein-142 vaccine |
| WO2015056244A1 (en) * | 2013-10-18 | 2015-04-23 | Universidade Federal De Minas Gerais - Ufmg | Kit and immunodiagnostic method for detecting anaemia caused by vivax malaria, synthetic peptides and uses |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744724B1 (en) * | 1996-02-14 | 2002-08-02 | Pasteur Institut | RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF PROTEIN MSP-1 OF A PLASMODIUM INFECTIOUS TO MAN FOR THE PRODUCTION OF ANTI-MALARIA VACCINES |
-
2000
- 2000-04-20 JP JP2000612331A patent/JP2002543774A/en active Pending
- 2000-04-20 WO PCT/GB2000/001558 patent/WO2000063245A2/en active Application Filing
- 2000-04-20 AU AU41330/00A patent/AU779662B2/en not_active Ceased
- 2000-04-20 CN CN00809259A patent/CN1372568A/en active Pending
- 2000-04-20 EP EP00920918A patent/EP1180120A2/en not_active Withdrawn
- 2000-04-20 MX MXPA01010701A patent/MXPA01010701A/en unknown
- 2000-04-20 BR BR0009823-0A patent/BR0009823A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000063245A2 (en) | 2000-10-26 |
| WO2000063245A9 (en) | 2002-08-29 |
| EP1180120A2 (en) | 2002-02-20 |
| AU4133000A (en) | 2000-11-02 |
| CN1372568A (en) | 2002-10-02 |
| JP2002543774A (en) | 2002-12-24 |
| MXPA01010701A (en) | 2003-08-20 |
| AU779662B2 (en) | 2005-02-03 |
| WO2000063245A3 (en) | 2001-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9811744A (en) | Conjugates containing antenapedia homeodomain | |
| AR019818A1 (en) | AN IMMUNOCONJUGADO DE MIOSTATINA. | |
| BR0207961A (en) | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases. | |
| CY1108007T1 (en) | PHARMACEUTICAL COMPOSITIONS OF BOTULINE TOXIN | |
| BR9710124A (en) | Process for preparing an olefin oxide Process for preparing propolene oxide and composition | |
| CL2010000018A1 (en) | Fragments of beta amyloid peptide (ab) ab 1-7 and ab 3-7 linked to a carrier peptide, a pharmaceutical composition that comprises it and its use to treat Alzheimer's disease | |
| IS2321B (en) | Methods and preparations for the prevention of bronchodilator tolerance | |
| TR200100056T2 (en) | Neurotrophic factors | |
| DK0960127T3 (en) | Isolated dimeric fibroblast activating protein alpha and uses thereof | |
| IT1267448B1 (en) | VACCINE FOR THE PREVENTION OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME. | |
| DE69716888T2 (en) | LEADERSHIP SYSTEM, ESPECIALLY FOR VISIBLE PEOPLE | |
| DK0988861T3 (en) | Stabilized protein preparations | |
| AU4110001A (en) | Polypeptide inducing apoptosis | |
| BR9913533A (en) | Processes for treating hypertension and compositions for use in them | |
| HUP0003762A3 (en) | Adipocyte-specific protein homologs | |
| DE59700522D1 (en) | MAGNETIC BRAKE, IN PARTICULAR LINEAR WHEELBREAK BRAKE | |
| BR0009823A (en) | Variant of the merozoite plasmodium (msp-1) surface protein and vaccine comprising the variant | |
| DE59703099D1 (en) | Self-adjusting plunger switch, especially car brake light switch | |
| EP1180999A4 (en) | Recombinant vaccine against botulinum neurotoxin | |
| NO995062D0 (en) | <Beta> -anyloid peptide binding proteins and polynuldeotides encoded for the same | |
| DE59703757D1 (en) | Electromagnetic switching valve | |
| PT929299E (en) | 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINS AND 2-AMINOCYCLOHEPTA ¬B | BENZOFURANOS SUBSTITUIDOS | |
| UA27997C2 (en) | EXTRACTION AGENT OF PERIPLASMATIVE RECOMBINANT PROTEIN, METHOD OF PREPARATION OF PERIPLASMATIC RECOMBINANT PROTEIN (OPTIONS), METHOD | |
| LV12177A (en) | Natural remedy for anti-glucocorticoids | |
| PT1276495E (en) | USING RECOMBINANT PULMONARY TENSIONS FOR THE EARLY TREATMENT OF ACUTE PULMONARY DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A,8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009. |